Comparisons of creatinine and cystatin C for detection of kidney disease and prediction of all-cause mortality in HIV-infected women

AIDS

Volumn 27, Issue 14, 2013, Pages 2291-2299

  Driver, Todd H ^a   Scherzer, Rebecca ^a   Peralta, Carmen A ^a,b   Tien, Phyllis C ^a,b   Estrella, Michelle M ^c   Parikh, Chirag R ^d,e   Butch, Anthony W ^f   Anastos, Kathryn ^g   Cohen, Mardge H ^h   Nowicki, Marek ⁱ   Sharma, Anjali ^j   Young, Mary A ^k   Abraham, Alison ^c   Shlipak, Michael G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d Section of Nephrology   (United States)

^e YALE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h RUSH UNIVERSITY   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j Downstate Health Sciences University   (United States)

^k GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Creatinine; Cystatin C; Glomerular filtration rate; HIV; Kidney; Mortality; Women

Indexed keywords

CREATININE; CYSTATIN C; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADULT; BIOLOGICAL MARKERS; CHRONIC DISEASE; COHORT STUDIES; CREATININE; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84884501823     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328362e874     Document Type: Article

References (47)

1. KDIGO CKD Work Group. 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013; 3:1-150.
2. Scherzer R, Heymsfield SB, Lee D, Powderly WG, Tien PC, Bacchetti P, et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS 2011; 25:1405-1414.
3. Yarasheski KE, Scherzer R, Kotler DP, Dobs AS, Tien PC, Lewis CE, et al. Age-related skeletal muscle decline is similar in HIVinfected and uninfected individuals. J Gerontol A Biol Sci Med Sci 2011; 66:332-340.
4. Lee FJ, Amin J, Bloch M, Pett SL, Marriott D, Carr A. Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults. J Acquir Immune Defic Syndr 2013; 62:525-533.
5. Richmond SR, Carper MJ, Lei X, Zhang S, Yarasheski KE, Ramanadham S. HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters. Biochim Biophys Acta 2010; 1801:559-566.
6. Barbieri M, Ferrucci L, Ragno E, Corsi A, Bandinelli S, Bonafe M, et al. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am J Physiol Endocrinol Metab 2003; 284:E481-487.
7. Kusko RL, Banerjee C, Long KK, Darcy A, Otis J, Sebastiani P, et al. Premature expression of a muscle fibrosis axis in chronic HIV infection. Skelet Muscle 2012; 2:10.
8. Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002; 61:195-202.
9. Szczech LA, Hoover DR, Feldman JG, Cohen MH, Gange SJ, Gooze L, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004; 39:1199-1206.
10. Krawczyk CS, Holmberg SD, Moorman AC, Gardner LI,McGwin G Jr. Factors associated with chronic renal failure in HIVinfected ambulatory patients. AIDS 2004; 18:2171-2178.
11. Gupta SK, Mamlin BW, Johnson CS, Dollins MD, Topf JM, Dube MP. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol 2004; 61:1-6.
12. Gardner LI, Holmberg SD, Williamson JM, Szczech LA, Carpenter CC, Rompalo AM, et al. Development of proteinuria or elevated serum creatinine and mortality in HIVinfected women. J Acquir Immune Defic Syndr 2003; 32: 203-209.
13. Eggers PW, Kimmel PL. Is there an epidemic of HIV Infection in the US ESRD program? J Am Soc Nephrol 2004; 15:2477-2485.
14. Szczech LA, Grunfeld C, Scherzer R, Canchola JA, van der Horst C, Sidney S, et al. Microalbuminuria in HIV infection. AIDS 2007; 21:1003-1009.
15. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26:867-875.
16. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 2010; 121:651-658.
17. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS 2010; 24:387-394.
18. Wyatt CM, Hoover DR, Shi Q, Seaberg E, Wei C, Tien PC, et al. Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr 2010; 55:73-77.
19. Wu I, Parikh CR. Screening for kidney diseases: older measures versus novel biomarkers. Clin J Am Soc Nephrol 2008; 3:1895-1901.
20. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473-2483.
21. Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011; 22:147-155.
22. Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005; 142:497-505.
23. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352:2049-2060.
24. Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011; 305:1545-1552.
25. Odden MC, Scherzer R, Bacchetti P, Szczech LA, Sidney S, Grunfeld C, et al. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med 2007; 167:2213-2219.
26. Choi A, Scherzer R, Bacchetti P, Tien PC, Saag MS, Gibert CL, et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis 2010; 56:872-882.
27. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998; 9:117-125.
28. Bacon MC, von Wyl V, Alden C, Sharp G, Robison E, Hessol N, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 2005; 12:1013-1019.
29. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612.
30. Inker LA, Eckfeldt J, Levey AS, Leiendecker-Foster C, Rynders G, Manzi J, et al. Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values. Am J Kidney Dis 2011; 58:682-684.
31. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20-29.
32. Inker LA, Wyatt C, Creamer R, Hellinger J, Hotta M, Leppo M, et al. Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals. J Acquir Immune Defic Syndr 2012; 61:302-309.
33. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145:247-254.
34. Hastie T, Tibshirani R. Generalized additive models. 1st ed. London; New York: Chapman and Hall; 1990.
35. Hoeting JA, Madigan D, Raftery AE, Volinsky CT. Bayesian model averaging: a tutorial. Statistical Sci 1999; 14:382-401.
36. Gilks WR, Richardson S, Spiegehalter DJ. Markov chain Monte Carlo in practice. London: Chapman & Hall; 1996.
37. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27:157-172; discussion 207-112.
38. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30:11-21.
39. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145:237-246.
40. JonesCY, JonesCA,WilsonIB, KnoxTA, LeveyAS, Spiegelman D, et al. Cystatin C and creatinine in an HIV cohort: the nutrition for healthy living study. Am J Kidney Dis 2008; 51:914-924.
41. Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG. Risk factors for ESRD in HIV-infected individuals: traditional and HIVrelated factors. Am J Kidney Dis 2012; 59:628-635.
42. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 2003; 14:2902-2907.
43. Tordato F, Cozzi Lepri A, Cicconi P, De Luca A, Antinori A, Colangeli V, et al. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med 2011; 12:4-13.
44. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24:1667-1678.
45. Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, Bertenthal D, et al. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis 2007; 45:1633-1639.
46. Praditpornsilpa K, Avihingsanon A, Chaiwatanarat T, Chaiyahong P, Wongsabut J, Ubolyam S, et al. Comparisons between validated estimated glomerular filtration rate equations and isotopic glomerular filtration rate in HIV patients. AIDS 2012; 26:1781-1788.
47. Bonjoch A, Bayes B, Riba J, Puig J, Estany C, Perez-Alvarez N, et al. Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. Antiviral Res 2010; 88:347-354.